Pathophysiology and emerging therapies for severe asthma

Session
Chairs: C. Lemiere (Montreal, Canada), I. Adcock (London, United Kingdom)
Aims: At the conclusion of the session participants will describe recent progress in identifying pathophysiological and biomarkers for severe asthma endotypes; describe clinical features that distinguish poorly controlled asthma; and identify and understand the effectiveness of emerging biologic therapies for steroid refractory poorly controlled asthma. This session is jointly organised by the Canadian Thoracic Society and the European Respiratory Society.

Diagnostic approach to and phenotyping of severe asthma E. Bel (Amsterdam, Netherlands)
Factors driving airway eosinophilia in prednisone-dependent severe asthma P. Nair (Hamilton, ON, Canada)
Pathophysiology of non-eosinophilic severe asthma R. Djukanovic (Southampton, United Kingdom)
Emerging biologic approaches for the treatment of difficult to control asthma J. Fitzgerald (Vancouver, BC, Canada)